Results of the clinical trial comparing heat stable carbetocin and oxytocin in prevention of postpartum haemorrhage

We are pleased to share the announcement of the results of the clinical trial comparing heat stable carbetocin and oxytocin in prevention of postpartum haemorrhage.

“The study, published today in the New England Journal of Medicine, has shown an alternative drug – heat-stable carbetocin – to be as safe and effective as oxytocin in preventing postpartum haemorrhage. This new formulation of carbetocin does not require refrigeration and retains its efficacy for at least 3 years stored at 30 degrees celsius and 75% relative humidity.”

WHO announcement:

http://www.who.int/news-room/detail/27-06-2018-who-study-shows-drug-could-save-thousands-of-women%E2%80%99s-lives

Link to study in the New England Journal of Medicine:

https://www.nejm.org/doi/full/10.1056/NEJMoa1805489

Merck for Mothers announcement:

http://www.mrknewsroom.com/news-release/corporate-news/merck-announces-findings-who-led-study-investigational-heat-stable-carbe

Ferring announcement:

https://www.ferring.com/en/media/press-releases/ferring-s-heat-stable-carbetocin-could-save-thousands-of-women-s-lives-by-preventing-excessive-bleeding-after-childbirth/

 

Menu